Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.
Telix has agreed to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, according to Fierce Biotech. The deal brings in an R&D pipeline anchored by a candidate that could compete directly with Novartis' Lutathera, a key product in the radiopharmaceutical market.
The acquisition also includes ITM's radiopharmaceutical supply network, which analysts say strengthens Telix's position in the space. The deal is seen as a strategic move into territory where Novartis has been a major player.
Analysts are described as 'extremely bullish' on the transaction, citing both the pipeline and the supply infrastructure. The deal highlights growing competition in targeted cancer therapies and radiopharmaceutical manufacturing.
Sources · 3
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Novo Nordisk seeks to reassure investors with new drug pipeline
At a capital markets day, Novo's CEO acknowledged investor doubts and outlined plans to compete with Eli Lilly and launch several multibillion-dollar products.